Rewrite Acquisition - Additional Information (Detail) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended		9 Months Ended
	Feb. 02, 2022	Jan. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Feb. 28, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Research and development			$ 113,696	$ 96,651	$ 326,088	$ 319,945
Common stock, shares issued			89,097,821		89,097,821			87,103,007
Rewrite Therapeutics Delaware Corporation Member
Business Acquisition [Line Items]
Upfront consideration payable in cash	$ 45,000
Research and development	56,000
Milestone payments	155,000
Cash	$ 130,000
Common stock, shares issued	25,000,000
Liability for milestone payment	$ 10,500	$ 25,000
Rewrite Therapeutics Delaware Corporation Member | Pre-specified Research Milestones [Member]
Business Acquisition [Line Items]
Milestone payments	55,000
Rewrite Therapeutics Delaware Corporation Member | Regulatory Approval Milestone [Member]
Business Acquisition [Line Items]
Milestone payments	$ 100,000
Rewrite Therapeutics Delaware Corporation Member | Rewrite Acquisition [Member]
Business Acquisition [Line Items]
Cash							$ 900
Common stock, shares issued in connection with research milestone		567,045